ozagrel

RN refers to (E)-isomer

Also Known As:

3-(4-(1H-imidazol-1-ylmethyl)phenyl)-2-propenoic acid; 4-(1-imidazoylmethyl)cinnamic acid; OKY 046; OKY-046; ozagrel, monohydrochloride; ozagrel, monohydrochloride, (E)-isomer; sodium ozagrel; 2-Propenoic acid, 3-(4-(1H-imidazol-1-ylmethyl)phenyl)-, (E)-

Networked: 235 relevant articles (36 outcomes, 45 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Acrylates: 212
      - Methacrylates: 609
        ozagrel: 235

Experts

1.	Bhatia, Pankaj: 3 articles (11/2021 - 01/2021)
2.	Singh, Nirmal: 3 articles (11/2021 - 01/2021)
3.	Irie, Tetsumi: 3 articles (01/2013 - 04/2004)
4.	Irikura, Mitsuru: 3 articles (01/2013 - 04/2004)
5.	Ishitsuka, Yoichi: 3 articles (01/2013 - 04/2004)
6.	Zhang, Jing: 2 articles (01/2020 - 05/2012)
7.	Xie, Yan-Ming: 2 articles (07/2019 - 12/2016)
8.	Guo, Sun-Wei: 2 articles (10/2016 - 10/2016)
9.	Liu, Xishi: 2 articles (10/2016 - 10/2016)
10.	Park, Sang In: 2 articles (03/2015 - 01/2010)

Related Diseases

1.	Stroke (Strokes) 05/01/2012 - "We searched seven databases, using the Cochrane Stroke Group search strategy and the terms of ozagrel and stroke. " 09/01/1996 - "The rates of suppressive effect in progressing stroke and complete recovery were higher in sodium ozagrel group. " 12/01/2016 - "We investigated whether ozagrel was beneficial for patients with atherothrombotic stroke or lacunar infarction. " 12/01/2016 - "Ordinal logistic regression analyses showed that ozagrel use was not significantly associated with modified Rankin Scale score at discharge in patients with atherothrombotic stroke (odds ratio: .99; 95% confidence interval: .88-1.11) or in those with lacunar infarction (odds ratio: 1.00; 95% confidence interval: .87-1.16). " 12/01/2016 - "Propensity score-matched analyses were performed separately for patients with atherothrombotic stroke and those with lacunar infarction, which balanced differences in baseline characteristics between patients who received ozagrel (ozagrel group) and those who did not (control group) in each stroke subtype. "
2.	Ischemic Stroke 05/01/2012 - "However, the evidence of ozagrel to reduce the long-term death or disability is limited and quality of these trials is insufficent hence, large-sample and high quality RCTs are warrented to confirm the efficacy of ozagrel for acute ischemic stroke." 05/01/2012 - "Ozagrel for acute ischemic stroke: a meta-analysis of data from randomized controlled trials." 12/01/2016 - "Ozagrel for Patients With Noncardioembolic Ischemic Stroke: A Propensity Score-Matched Analysis." 01/01/2020 - "Therefore, much attention has been paid to develop a novel therapeutic compound, paeonol-ozagrel conjugate (POC), for ischemic stroke. " 01/01/2020 - "Synthesis of Paeonol-Ozagrel Conjugate: Structure Characterization and In Vivo Anti-Ischemic Stroke potential."
3.	Cerebral Infarction 05/01/2005 - "With the initial diagnosis of cerebral infarction, we started therapy using sodium ozagrel. " 07/01/1986 - "OKY-046 at a dose of 0.3 mg/kg (i.v.) prevented the arachidonate-induced sudden death and also decreased the incidence of cerebral infarction induced by injection of arachidonate into the internal carotid artery in rabbits. " 01/01/2003 - "Effect of ozagrel, a selective thromboxane A2-synthetase inhibitor, on cerebral infarction in rats. " 02/01/1998 - "Therefore, sodium ozagrel was clinically more efficient and safer than urokinase in patients with acute cerebral infarction." 02/01/1998 - "[Clinical effects of sodium ozagrel and urokinase in patients with acute cerebral infarction in the territory of the internal carotid artery]."
4.	Ischemia 05/27/1996 - "However, renal functional parameters were significantly improved with the 2 mg/kg dose of OKY-046 administered after renal ischemia. " 08/01/1997 - "Twenty-eight heart were divided into four experimental groups consisting of 7 hearts each; Group I consisted of controls with zero-flow ischemia; Group II, perfusion with OKY-046 (10(-6) M) in zero-flow ischemia; Group III, controls with low-flow ischemia; and Group IV, perfusion with OKY-046 in low-flow ischemia. " 08/01/1997 - "OKY-046 was administered from forty-five minutes prior to the global ischemia. " 01/01/1997 - "Treatment with OKY-046 prevented the ischemia-induced reduction in the fetal body and placental weights. " 07/01/1996 - "Immediately after forebrain ischemia, OKY-046 (10 mg/kg) was injected intraperitoneally into the treated group. "
5.	Lacunar Stroke 12/01/1996 - "Sodium ozagrel is considered to be effective in the acute phase of lacunar infarction." 12/01/2016 - "The present study suggested that ozagrel was safe to use but did not improve functional outcomes in patients with atherothrombotic or lacunar infarction." 11/01/2004 - "The sodium ozagrel is recommended in the treatment of acute lacunar infarction. " 12/01/2016 - "We investigated whether ozagrel was beneficial for patients with atherothrombotic stroke or lacunar infarction. " 12/01/2016 - "Ordinal logistic regression analyses showed that ozagrel use was not significantly associated with modified Rankin Scale score at discharge in patients with atherothrombotic stroke (odds ratio: .99; 95% confidence interval: .88-1.11) or in those with lacunar infarction (odds ratio: 1.00; 95% confidence interval: .87-1.16). "

Related Drugs and Biologics

1.	Thromboxanes
2.	ozagrel
3.	Edaravone
4.	Thromboxane-A Synthase
5.	Ligases (Synthetase)
6.	Sodium
7.	Epoprostenol (Prostacyclin)
8.	Creatinine
9.	Glycerol (Glycerine)
10.	Thromboxane A2 (A2, Thromboxane)

Related Therapies and Procedures

1.	Therapeutics
2.	Activities of Daily Living (ADL)
3.	Thrombolytic Therapy
4.	Intravenous Administration
5.	Hepatectomy